Tickers

1. Composite Trajectory Verdict

For a clinical-stage biotechnology company with no product revenue, the income statement (collaboration revenue growth and loss trajectory) and balance sheet (cash runway and equity position) carry the most weight, as they directly reflect the company's ability to fund development toward potential future value inflection points.

Composite Trajectory: Improving

The income statement shows collaboration revenue growing 154% year-over-year to $72.3 million in FY2025 (10-K 2025-12-31, Consolidated Statements of Operations) and 39% in Q2 2026 vs. Q2 2025 to $13.4 million (10-Q 2026-06-30, Condensed Statements of Operations), while net loss narrowed from -$40.2 million to -$6.1 million annually and from -$10.2 million to -$3.9 million in Q2. The balance sheet strengthened with cash and marketable securities rising from $112.1 million at December 2024 to $248.1 million at December 2025 (10-K 2025-12-31, Consolidated Balance Sheets) and $320.4 million at June 2026 (10-Q 2026-06-30, Note 4), and total stockholders' equity increasing from $33.4 million to $206.8 million to $305.6 million over the same periods. Operating cash burn improved from -$51.1 million to -$41.1 million annually and from -$40.2 million to -$37.6 million for the first six months (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). No statement shows a deteriorating trend.

2. Red Flags

• Heavy reliance on equity financing for liquidity: Net cash from financing activities was $174.7 million in FY2025 and $108.9 million in the first half of 2026, dwarfing operating cash outflows (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows).
• Accumulated deficit continues to grow: Increased from -$825.9 million at December 2024 to -$832.0 million at December 2025 (10-K 2025-12-31, Consolidated Balance Sheets) and to -$845.0 million at June 2026 (10-Q 2026-06-30, Consolidated Balance Sheets).
• Large warrant overhang: 10.9 million warrants and pre-funded warrants outstanding at June 30, 2026, including 4.5 million Class B warrants expiring December 31, 2026 unless $75 million in non-dilutive collaboration capital is announced by November 15, 2026 (10-Q 2026-06-30, Note 6).
• Deferred revenue declining without new large upfront payments: Current deferred revenue fell from $36.9 million at December 2025 to $16.3 million at June 2026, and long-term deferred revenue went from $35.4 million to $0 (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets), reflecting recognition of existing contract liabilities without replacement.

3. Earnings Assessment

Earnings Trajectory: Improving

Collaboration revenue rose from $28.5 million in FY2024 to $72.3 million in FY2025 (10-K 2025-12-31, Consolidated Statements of Operations), driven by a $35 million license fee recognized upon Gilead's HPI program option exercise in December 2025. In Q2 2026, revenue increased 39% year-over-year to $13.4 million, including a $5.1 million cumulative catch-up adjustment from revised cost estimates (10-Q 2026-06-30, Condensed Statements of Operations; Note 8). Research and development expenses grew 16% annually to $64.8 million but declined 7% in Q2 2026 and 4% for the first six months versus the prior year (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A). General and administrative expenses rose 9% annually and 4-5% in recent quarters. Net loss narrowed from -$40.2 million in FY2024 to -$6.1 million in FY2025, from -$10.2 million to -$3.9 million in Q2, and from -$19.0 million to -$12.9 million for the first six months (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Condensed Statements of Operations).

4. Cash Generation Assessment

Cash Trajectory: Improving

Net cash used in operating activities improved from -$51.1 million in FY2024 to -$41.1 million in FY2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows) and from -$40.2 million to -$37.6 million for the first six months of 2026 versus 2025 (10-Q 2026-06-30, Consolidated Statements of Cash Flows). The improvement was attributed to higher collaboration cash receipts ($25.2 million more in FY2025) and lower clinical expenditures following trial completions. Financing activities provided $174.7 million in FY2025 (primarily an August 2025 offering) and $108.9 million in the first half of 2026 (a May 2026 underwritten offering), while investing activities consumed $113.5 million and $97.5 million respectively, reflecting purchases of marketable securities with offering proceeds (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). Total cash, cash equivalents, and marketable securities increased from $112.1 million at December 2024 to $248.1 million at December 2025 to $320.4 million at June 2026 (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, Note 4).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total assets grew from $119.2 million at December 2024 to $257.6 million at December 2025 to $330.8 million at June 2026, driven by cash and marketable securities rising from $112.1 million to $248.1 million to $320.4 million (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets; Note 4). Total liabilities fell from $85.8 million to $50.8 million to $25.2 million, primarily as deferred revenue (a contract liability) was recognized—current portion from $37.6 million to $36.9 million to $16.3 million, long-term from $35.4 million to $0 to $0 (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Total stockholders' equity increased from $33.4 million to $206.8 million to $305.6 million, supported by $174.7 million and $108.9 million in net financing proceeds (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). The accumulated deficit grew modestly from -$825.9 million to -$832.0 million to -$845.0 million over the same periods.

6. Data Gaps

• Quarterly financial statements for Q3 2025 and Q4 2025 (only annual FY2025 data provided in 10-K)
• Complete Q1 2026 financial statements (10-Q for March 31, 2026 provides MD&A but truncated financial statement data)
• Detailed breakdown of operating lease maturities beyond the $3.2 million total disclosed at December 2025
• Historical product revenue (none reported to date per all filings)
• Full year 2026 projections beyond management's cash runway estimates